𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chronic hepatitis C in african americans and other minority groups

✍ Scribed by Jaquelyn Fleckenstein

Publisher
Springer
Year
2004
Tongue
English
Weight
193 KB
Volume
6
Category
Article
ISSN
1522-8037

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Selective decrease in hepatitis C virus–
Selective decrease in hepatitis C virus–specific immunity among African Americans and outcome of antiviral therapy
✍ Hugo R. Rosen; Scott J. Weston; KyungAh Im; Huiying Yang; James R. Burton Jr.; H πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 218 KB πŸ‘ 1 views

Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, end-stage liver disease, and hepatocellular carcinoma throughout the world. Considerable evidence indicates that the risk of viral persistence, natural history, and response to antiviral therapy varies among racial groups, bu

Hepatitis C virus antibodies among risk
Hepatitis C virus antibodies among risk groups in a South African area endemic for hepatitis B virus
✍ Dr. P. N. Soni; D. R. Tait; D. G. Kenoyer; F. Fernandes-Costa; S. Naicker; W. Go πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 468 KB

## Abstract The prevalence of anti‐HCV was studied in a South African area endemic for hepatitis B virus. A total of 35,685 volunteer blood donors (22,034 whites, 9,218 Asians, 3,077 Africans, 1,356 coloureds), 71 haemophiliacs, 84 chronic dialysis patients, 100 antenatal attenders, 212 nurses, and

Impact of weight-based ribavirin with pe
Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1
✍ Ira M. Jacobson; Robert S. Brown Jr; Jonathan McCone; Martin Black; Clive Albert πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 313 KB πŸ‘ 1 views

Brass, 14 for the WIN-R Study Group WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PEG-IFN) alfa-2b